Nanjing Vcare CDMO Business Technology Center was Established and Put Into Operation

2022-04-13

In April 2022, Nanjing Vcare CDMO Business Technology Center was completed and operated, marking a solid step for the company to provide high-quality and large-scale CDMO services for domestic and foreign pharmaceutical companies.

Vcare PharmaTech has built a new innovative chiral synthesis technology platform, a continuous flow technology platform laboratory, and a biological enzyme engineering technology laboratory, covering metal catalysis technology, flow chemistry technology, fixed bed hydrogenation technology, and molecular biology transformation, biological enzyme fermentation and catalytic technology. The new purchase of micro-filled bed pilot and pilot test equipment, Pilot1500MRT microchannel reactor, PCR instrument, enzyme label instrument and 400M Bruker nuclear magnetic and other high-end instruments has strategic significance for CDMO R & D and high-quality development of production business.

The use of the new technology platform laboratory will further enhance the ability of Nanjing Vcare to provide global partners with professional, rapid, efficient, high-quality, comprehensive and cost-effective drug research and development services across the entire industry chain.

Looking back on the development of Vcare PharmaTech for more than ten years, starting from less than 200 square meters of laboratory, all the way to today, with a self-built 21000 square meters of research and development center, It has built a professional technology platform for targeted innovative drug development, computer-aided drug design, multi-chiral complex drug synthesis and separation technology, complex drug preparation development, crystal salt screening, bioenzyme engineering technology and continuous flow engineering technology, and has nearly 300 pilot synthesis ventilation cabinets, 45 kg laboratory ventilation rooms. It has more than 200 sets (sets) of international first-class experimental equipment for various kinds of analysis, preparation, synthesis, biology, pharmacology and toxicology, and assists customers to obtain 20 drug registration approvals and 10 clinical approvals, is registering more than 50 applications, and supplies more than 3,000 customized intermediates and API. In 2021, the revenue of CRO/CDMO industrial chain service business will exceed 200 million yuan.

At present, the company has the capacity of CDMO production and supply services from pharmaceutical intermediates to API, and the integrated service capacity of the whole industry chain from pharmaceutical CMC to clinical CRO research and registration, helping customers to quickly obtain production approval and clinical trial approval, and effectively responding to the cost pressure of national collection and medical insurance negotiations. The core competitiveness of the pharmaceutical industry lies in R & D innovation, Nanjing Vcare will continue to increase investment in R & D, continue to build the company's scientific and technological hard strength, and provide a strong guarantee for high-quality CRO/CDMO industry chain services for domestic and foreign customers.

Prev

Nanjing Vcare was Recognized as a "Small and Medium-sized Science and Technology Enterprise in Jiangsu Province"

Next

Nanjing Vcare Assists Hualon Pharmaceutical in Passing the Conformity Evaluation for Omeprazole Sodium and Pantoprazole Sodium